Adaptive Biotechnologies (ADPT) Non-Current Deffered Revenue (2018 - 2026)

Adaptive Biotechnologies has disclosed Non-Current Deffered Revenue across 9 years of filings, most recently posting $608000.0 for Q2 2026.

• In Q2 2026, Non-Current Deffered Revenue fell 96.96% year-over-year to $608000.0; the TTM figure through Jun 2026 stood at $608000.0 (down 96.96% YoY), while the FY2025 annual figure was $1.0 million, down 96.31% from the prior year.
• Non-Current Deffered Revenue came in at $608000.0 for Q2 2026 at Adaptive Biotechnologies, down from $807000.0 in the prior quarter.
• In the past five years, Non-Current Deffered Revenue ranged from a high of $84.9 million in Q1 2022 to a low of $608000.0 in Q2 2026.
• Average Non-Current Deffered Revenue over 5 years is $37.2 million, with a median of $41.5 million recorded in 2024.
• Year-over-year, Non-Current Deffered Revenue fell 18.08% in 2024 and sank 96.96% in 2026.
• Over 5 years, Non-Current Deffered Revenue stood at $58.6 million in 2022, then retreated by 23.56% to $44.8 million in 2023, then plunged by 39.15% to $27.3 million in 2024, then slumped by 96.31% to $1.0 million in 2025, then slumped by 39.56% to $608000.0 in 2026.
• Per Business Quant data, the three most recent Non-Current Deffered Revenue figures were $608000.0 in Q2 2026, $807000.0 in Q1 2026, and $1.0 million in Q4 2025.